[Skip to Navigation]
Sign In
Comment & Response
January 13, 2022

Hypofractionated Radiotherapy for Locally Advanced Non–Small Cell Lung Cancer—Does Size Matter?

Author Affiliations
  • 1Department of Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York
  • 2Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
JAMA Oncol. 2022;8(3):480-481. doi:10.1001/jamaoncol.2021.7157

To the Editor We would like to congratulate Dr Iyengar and colleagues for executing an important randomized clinical trial comparing 2 radiotherapy schedules for patients with stage II/III non–small cell lung cancer who are ineligible for concurrent chemoradiotherapy.1 While the trial did not meet its primary end point, the study team has demonstrated the feasibility of a clinical trial in this patient population and generated important data to inform future efforts.

Add or change institution